Gilead Sciences (GILD) Prepaid Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Prepaid Assets came in at $4.3 billion in Q1 2026, up 53.54% YoY from $2.8 billion in Q1 2025, and up 7.9% on a QoQ basis from $4.0 billion in Q4 2025.
Gilead Sciences (GILD) Prepaid Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Prepaid Assets data on file, last reported at $4.3 billion in Q1 2026.
- Quarterly Prepaid Assets rose 53.54% year-over-year to $4.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 53.54% YoY) and the FY2025 annual result came in at $4.0 billion, up 31.85% from the prior year.
- Prepaid Assets improved to $4.3 billion in Q1 2026, from $4.0 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.3 billion in Q1 2026 to a low of $1.8 billion in Q2 2023.
- A 5-year average of $2.7 billion and a median of $2.8 billion in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets fell 17.14% — and 2024, when it soared 62.55%.
- Tracing GILD's Prepaid Assets over 5 years: stood at $1.8 billion in 2022, then soared by 33.82% to $2.4 billion in 2023, then increased by 28.56% to $3.1 billion in 2024, then soared by 31.85% to $4.0 billion in 2025, then advanced by 7.9% to $4.3 billion in 2026.
- The last three Prepaid Assets figures came in at $4.3 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.76 Bn |
| Mar 31, 2026 | 4.34 Bn |
| Dec 31, 2025 | 4.02 Bn |
| Sep 30, 2025 | 3.65 Bn |
| Jun 30, 2025 | 2.90 Bn |
| Mar 31, 2025 | 2.83 Bn |
| Dec 31, 2024 | 3.05 Bn |
| Sep 30, 2024 | 3.29 Bn |
| Jun 30, 2024 | 2.86 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 2.37 Bn |
| Sep 30, 2023 | 2.66 Bn |
| Jun 30, 2023 | 1.76 Bn |
| Mar 31, 2023 | 1.85 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 2.08 Bn |
| Jun 30, 2022 | 1.90 Bn |
| Mar 31, 2022 | 2.04 Bn |
| Dec 31, 2021 | 2.14 Bn |
| Sep 30, 2021 | 2.01 Bn |